Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary

Elizabeth M Sherman^{1

2}, Allison L Agwu³, Juan Ambrosioni^{4

5

6}, Georg M N Behrens^{7

8

9}, Carolyn Chu¹⁰, Lauren F Collins¹¹, Humberto R Jimenez^{12

13}, David E Koren¹⁴, Leslie McGorman¹⁵, Nancy N Nguyen¹⁶, Melanie R Nicol¹⁷, Neha Sheth Pandit¹⁸, Natacha Pierre¹⁹, Kimberly K Scarsi²⁰, Gary F Spinner²¹, Alice Tseng^{22

23}, Jeremy D Young²⁴, Melissa E Badowski²⁵

Affiliations

¹ Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.
² Division of Infectious Disease, Memorial Healthcare System, Hollywood, Florida, USA.
³ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ HIV Unit and Infectious Disease Service, Hospital Clinic and Fundació de Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.
⁵ University of Barcelona, Barcelona, Spain.
⁶ CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
⁷ Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
⁸ German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
⁹ Centre for Individualized Infection Medicine (CiiM), Hannover Medical School, Hannover, Germany.
¹⁰ University of California San Francisco, San Francisco, California, USA.
¹¹ Division of Infectious Diseases, Emory School of Medicine, Grady Ponce de Leon Center, Atlanta, Georgia, USA.
¹² Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.
¹³ Comprehensive Care Center, St. Joseph's University Medical Center, Paterson, New Jersey, USA.
¹⁴ Temple University Health System, Philadelphia, Pennsylvania, USA.
¹⁵ American Academy of HIV Medicine, Washington, District of Columbia, USA.
¹⁶ University of the Pacific, Thomas J. Long School of Pharmacy, Stockton, California, USA.
¹⁷ Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
¹⁸ Department of Practice, Sciences, and Health Outcomes Research, University of Maryland Baltimore School of Pharmacy, Baltimore, Maryland, USA.
¹⁹ Department of Population Health Nursing Science, College of Nursing, University of Illinois at Chicago, Chicago, Illinois, USA.
²⁰ Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
²¹ Southwest Community Health Center, Bridgeport, Connecticut, USA.
²² Immunodeficiency Clinic, University Health Network, Toronto, Ontario, Canada.
²³ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
²⁴ Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
²⁵ College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.

PMID: 39005161
DOI: 10.1002/phar.2921

Practice Guideline

Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary

Elizabeth M Sherman et al. Pharmacotherapy. 2024 Jul.

. 2024 Jul;44(7):488-493.

doi: 10.1002/phar.2921.

Authors

Affiliations

¹ Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.
² Division of Infectious Disease, Memorial Healthcare System, Hollywood, Florida, USA.
³ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ HIV Unit and Infectious Disease Service, Hospital Clinic and Fundació de Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.
⁵ University of Barcelona, Barcelona, Spain.
⁶ CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
⁷ Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
⁸ German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
⁹ Centre for Individualized Infection Medicine (CiiM), Hannover Medical School, Hannover, Germany.
¹⁰ University of California San Francisco, San Francisco, California, USA.
¹¹ Division of Infectious Diseases, Emory School of Medicine, Grady Ponce de Leon Center, Atlanta, Georgia, USA.
¹² Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.
¹³ Comprehensive Care Center, St. Joseph's University Medical Center, Paterson, New Jersey, USA.
¹⁴ Temple University Health System, Philadelphia, Pennsylvania, USA.
¹⁵ American Academy of HIV Medicine, Washington, District of Columbia, USA.
¹⁶ University of the Pacific, Thomas J. Long School of Pharmacy, Stockton, California, USA.
¹⁷ Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
¹⁸ Department of Practice, Sciences, and Health Outcomes Research, University of Maryland Baltimore School of Pharmacy, Baltimore, Maryland, USA.
¹⁹ Department of Population Health Nursing Science, College of Nursing, University of Illinois at Chicago, Chicago, Illinois, USA.
²⁰ Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
²¹ Southwest Community Health Center, Bridgeport, Connecticut, USA.
²² Immunodeficiency Clinic, University Health Network, Toronto, Ontario, Canada.
²³ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
²⁴ Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
²⁵ College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.

PMID: 39005161
DOI: 10.1002/phar.2921

Abstract

Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment - cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs in routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements of safe and optimal use of LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are identified and discussed.

Keywords: HIV; antiretrovirals; long acting; prevention; pre‐exposure prophylaxis; treatment.

PubMed Disclaimer

References

REFERENCE

1. Sherman EM, Agwu AL, Ambrosioni J, et al. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1. Pharmacotherapy. 2024; (awaiting publication).

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

Article Publication Charge provided by Pharmacotherapy Publications, Inc.

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Affiliations

Authors

Affiliations

Abstract

References

REFERENCE

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical